Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeGAL: Chemo-Genomics in Relapsed/Refractory AML
NCT02619071Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Open-label trial in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Primary endpoint: Proportion of patients for whom a tailored treatment could be proposed within 21 days. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02619071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619071.